Biomea Fusion Q1 net loss $12.4M; cash $45.1M; icovamenib Phase II T2D data due Q4 2026

Biomea Fusion, Inc.

2026-Q1 EPS reported -$0.17 vs consensus -$0.24 ▲ beat (+29.8%)

Net loss $12.4M ($1.6M SBC) vs $29.3M in Q1 2025; cash, equivalents & restricted cash $45.1M at Mar 31, 2026; runway into Q1 2027.
R&D expenses $9.1M (down from $22.9M YoY); G&A $3.7M (down from $6.8M).
Icovamenib chronic tox studies completed; Phase II T2D trials COVALENT-211/-212 dosing; topline 26-week data expected Q4 2026.
Phase II T1D COVALENT-112: 52% C-peptide AUC increase at week 12 (200mg); preservation through week 52; plan for investigator-sponsored trial.
Phase I GLP-1 obesity trial (BMF-650, GLP-131) ongoing; initial 28-day weight data expected Q2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Biomea Fusion, Inc. reported first quarter ended March 31, 2026 results: net income net loss of $12.4 million.

Period: first quarter ended March 31, 2026
Net income: net loss of $12.4 million
Result: reported results

Exact text from the filing

Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 2026

View on SEC.gov

Browse all earnings releases →

Biomea Fusion, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-217037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.